# NCT05607095 (NCT05607095)

> A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05607095
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Uveal Melanoma; Melanoma; Metastatic Uveal Melanoma; Metastatic Melanoma
- Interventions: Lifileucel (LN-144/LN-145)
- Enrollment: 40
- Primary outcome: Adverse events as evaluated by CTCAE v5.0

## Indexed commentary on NCT05607095 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05607095
